Skip to content

    Krishna Institu.

    KIMSGood
    Healthcare·7 Aug 2025
    Management Summary

    KIMS reported strong top-line growth driven by expansion, but margins faced significant pressure from the operationalization of new units in Thane, Nashik, and Kerala. Management is focused on a heavy expansion phase, with two large Bangalore units (~800 beds) set to commission in Q2 FY26. While mature clusters in Telangana and Andhra continue to grow steadily, the near-term focus is on neutralizing losses from greenfield projects and navigating insurance empanelment delays.

    Highlights

    8
    • Total revenue reached ₹879 crores, representing a 26.8% YoY growth and 9.6% QoQ growth.

    • EBITDA stood at ₹200 crores, up 8.5% YoY but down 1.4% on a sequential basis.

    • EBITDA margins compressed to 22.7% from 26.6% YoY, primarily due to losses from new units.

    • Net Profit (PAT) declined to ₹85 crores compared to ₹95 crores in Q1 FY25.

    • New unit losses in Q1 totaled ₹21 crores, with Thane contributing ~₹11 crores and Nashik ~₹7 crores.

    • Net debt as of June 30, 2025, stood at ₹2,020 crores.

    • Company-level ARPOB is targeted to reach ₹50,000-₹55,000 over the next 2-3 years from the current ~₹43,000 level.

    • Bed capacity expanded to 8,000 beds across 25 centers in 5 states.

    Concerns

    1
    • Insurance Empanelment Delays

    Key financials

    Single quarter

    06 metrics
    1. 01Total Revenue₹879 Cr+26.8%YoY
    2. 02EBITDA₹200 Cr+8.5%YoY
    3. 03EBITDA Margin22.7%
    4. 04PAT₹85 Cr-10.5%YoY
    5. 05Consolidated EPS₹1.96-9.2%YoY

    Segment breakdown

    Telangana Cluster
    6% Volume Growth70% Occupancy Target
    Maharashtra Cluster (Nashik/Thane)
    ₹18 Cr Q1 EBITDA Loss₹9 Cr Thane Revenue (July)
    Andhra Pradesh Cluster
    25,000 Rs ARPOB
    List

    Guidance & targets

    5
    CategoryTargetPriority
    Margin
    EBITDA Margin
    22% to 25%
    Medium
    Revenue
    Company-level ARPOB
    ₹50,000-₹55,000
    High
    Profitability
    Bangalore Units EBITDA Breakeven
    Neutral
    Medium
    Profitability
    Nashik Unit EBITDA Neutralization
    Neutral
    High
    Other
    ARPOB Growth (Mature Clusters)
    4-5%
    High

    Risks & concerns

    5
    RiskSeverity

    Insurance Empanelment Delays

    Full empanelment takes 9-12 months in new clusters, causing patient leakage to competitors who offer cashless facilities.Both acknowledged

    high

    High Debt Levels

    Net debt has reached ₹2,020 crores due to aggressive expansion, though management plans to use O&M models to mitigate further debt.Analyst acknowledged

    medium

    Doctor Onboarding Costs

    Pre-operative expenses and high doctor costs in new units (like Srikakulam and Bangalore) are dragging down consolidated margins.Management acknowledged

    medium

    Areas of Evasion(2)

    • Specific ARPOB for 'Congo' specialties (oncology/cardiology) was not provided off-hand.
    • Peak revenue potential for existing capacity was deferred for later analysis.

    Q&A highlights

    3

    “The combined losses in Q1 is INR21 crores... for Q2, we should have a loss of around INR8 to INR10 crores [from Nashik/Thane]... Bangalore will be another INR10 crore drag for the month of September.”

    Quantifies the significant margin headwind from the current expansion phase and provides a timeline for when these assets will stop bleeding.

    asked by Damayanti Kerai, HSBC

    2 min read5 chapters

    Detailed Narrative

    01

    Expansion Phase Impacts Near-Term Profitability

    KIMS is currently in a high-intensity expansion phase, which resulted in a ₹21 crore EBITDA loss from new units in Q1 FY26. The Thane unit contributed ₹11 crores to this loss, while Nashik added ₹7 crores. Management expects these losses to persist in Q2, with an incremental drag of ₹10-15 crores expected from the upcoming Bangalore units in September. Despite this, the consolidated revenue grew 26.8% YoY to ₹879 crores, showing strong underlying demand.

    02

    Maharashtra Cluster Facing Empanelment Hurdles

    The ramp-up in the Maharashtra cluster, particularly Nashik, has been slower than anticipated due to delays in insurance and CGHS empanelment. Management noted that insurance/CGHS typically accounts for 60% of volumes in these markets. While the cash business in Nashik has reached ₹7 crores monthly, full empanelment is expected to take another 3-6 months. Thane, however, showed a more promising start with ₹9 crores in revenue for the month of July.

    03

    Bangalore Entry to Drive ARPOB Expansion

    KIMS is set to operationalize two units in Bangalore with a combined capacity of ~800 beds in Q2 FY26. These units are critical to the company's strategy to increase network-level ARPOB from the current ~₹43,000 to a target range of ₹50,000-₹55,000. Management expects these facilities to reach EBITDA neutrality within 12 months of operation, contingent on reaching 30-40% occupancy.

    04

    Steady Growth in Mature Telangana and AP Clusters

    The mature clusters in Telangana and Andhra Pradesh continue to deliver steady performance with 5-6% volume growth. While Telangana is operating at high occupancy, the company is adding capacity in Kondapur and Gachibowli to sustain growth. In Andhra Pradesh, the focus is on improving the specialty mix by adding oncology and mother-and-child care, though management admits an ARPOB gap will always exist between AP and the higher-paying Telangana/Maharashtra markets.

    05

    Strategic Pivot Toward O&M Model

    To manage the high debt levels (₹2,020 crores) and operational bandwidth, KIMS is increasingly looking at the Operations & Management (O&M) model. Currently, units like Sangli and Guntur are operational under this model and have already achieved breakeven. Management believes the O&M model is a 'better model' for future expansion as it requires no capex commitment while allowing KIMS to take a share of the revenue.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.